PureTech Health PLC 2024 AR2
The report highlights PureTech Health plc's achievements in 2024, including the U.S. FDA approval of Cobenfy (formerly KarXT) for schizophrenia, which was invented at PureTech. The company also launched Seaport Therapeutics, securing over $325 million in Series A and B financings, and announced positive Phase 2b trial results for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis. Financially, PureTech maintained a strong balance sheet with $367 million in consolidated cash and returned $100 million to shareholders through a Tender Offer. On the ESG front, the company reduced energy consumption and greenhouse gas emissions at its Boston headquarters while continuing to align with SASB, TCFD, and UN SDG frameworks.
Company: PureTech Health PLC
Sector: Professional & technical services
Country: United States
Year: 2024
Type: AR2
Pages: 113
Back to company
PureTech Health PLC
Annual Report And Accounts
The report highlights PureTech Health plc's achievements in 2024, including the U.S. FDA approval of Cobenfy (formerly KarXT) for schizophrenia, which was invented at PureTech. The company also launched Seaport Therapeutics, securing over $325 million in Series A and B financings, and announced positive Phase 2b trial results for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis. Financially, PureTech maintained a strong balance sheet with $367 million in consolidated cash and returned $100 million to shareholders through a Tender Offer. On the ESG front, the company reduced energy consumption and greenhouse gas emissions at its Boston headquarters while continuing to align with SASB, TCFD, and UN SDG frameworks.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Total Waste
Women on Board
Women in Management
Employees